文献速递皮肤肿瘤

放疗对比咪喹莫特治疗复杂性恶性雀斑样痣:3期随机临床试验

Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial.
PubMed 文献 · J Am Acad Dermatol · 2025-07-17

这项多中心3期随机试验纳入不适合手术的恶性雀斑样痣患者126例,随机接受放疗或咪喹莫特治疗。主要终点24个月治疗失败率两组均低(放疗组12例失败,咪喹莫特组6例失败;两种治疗耐受良好,长期皮肤症状和健康相关生活质量无显著差异,但试验因提前终止招募而把握度不足。

要点

  • 放疗和咪喹莫特对不适合手术的恶性雀斑样痣均有效且耐受良好
  • 24个月治疗失败率两组均低,放疗组12例、咪喹莫特组6例,差异无统计学意义
  • 两组6个月缓解率均为95%,长期健康相关生活质量无显著差异

核心结论

  • 放疗和咪喹莫特均为恶性雀斑样痣有效且耐受良好的治疗,24个月内对健康相关生活质量无负面影响。

研究设计与样本

  • 多中心、3期、随机临床试验,2015年8月至2021年11月开展,126例患者随机分配至放疗或咪喹莫特组。

主要发现

  • 6个月缓解率两组均为95%。
  • 两组急性皮肤毒性主要为1级和2级,长期皮肤症状或健康相关生活质量无显著差异。
  • 两组治疗后情绪评分均显著优于基线。

临床怎么用

  • 对于不适合手术的恶性雀斑样痣患者,放疗或咪喹莫特均可作为非手术治疗选择。

局限性

  • 试验因提前终止招募而把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with lentigo maligna who are not suitable for surgery, radiotherapy, or topical imiquimod are alternative nonsurgical treatments. OBJECTIVE: This trial aimed to assess the efficacy, safety, and patient-reported health-related quality of life (HRQL). METHODS: A multiinstitutional, phase 3, randomized trial conducted between August 2015 and November 2021. Patients were randomized to radiotherapy or imiquimod. The primary end point was treatment failure at 24 months. Secondary end points included response at 6 months, development of invasive disease, toxicity and HRQL. RESULTS: Between August 2015 and November 2021, 126 patients were randomized. The response rate was 95% at 6 months in both groups. The treatment failure rates were low with 12 failures in the radiotherapy group and 6 in the imiquimod group at 24 months (Odd ratios, 2.35; 95% CI, 0.82-6.75; P = .11). Both were well-tolerated with mainly grade 1 and 2 acute skin toxicity with no significant differences between groups in skin symptoms or HRQL at long-term. Patients had significantly better emotional scores after treatment than at baseline in both groups. The trial is underpowered due to early cessation of recruitment. CONCLUSIONS: Both radiotherapy and imiquimod are efficient and well-tolerated treatments for lentigo maligna. Neither have negative impacts on HRQL at 24 months.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Hong AM, Lo SN, Fogarty GB, et al. Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial. J Am Acad Dermatol. 2025. PMID: 40683357. doi:10.1016/j.jaad.2025.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。